Alzamend Neuro
ALZN
12 hedge funds and large institutions have $3.26M invested in Alzamend Neuro in 2026 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 3 closing their positions.
351% more capital invested
Capital invested by funds: $723K → $3.26M (+$2.54M)
53.55% more ownership
Funds ownership: 17.93% → 71.48% (+54%)
8% less funds holding
Funds holding: 13 → 12 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KWM
KMT Wealth Management
El Segundo,
California
|
+$1.47M |
| 2 |
KCIA
Kingsbury Capital Investment Advisors
Wilmette,
Illinois
|
+$845K |
| 3 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$3.5K |
| 4 |
IA
IFG Advisory
Atlanta,
Georgia
|
+$24 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$21.4K |
| 2 |
Morgan Stanley
New York
|
-$19.1K |
| 3 |
CA
Clearstead Advisors
Cleveland,
Ohio
|
-$10.6K |
| 4 |
Citigroup
New York
|
-$5.54K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.96K |
ALZN Hedge Fund Activity: Q2 2026 in Review
12 of the 8,343 institutional investors tracked by Wall St. Rank reported a position in Alzamend Neuro (ALZN) for Q2 2026, worth a combined $3.26M — up 351% from $723K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ALZN and 2 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 2 added.
The largest buyer was KMT Wealth Management, opening a new position worth an estimated $1.47M. The largest seller was Geode Capital Management, cutting an estimated $21.4K.
- 12 institutional investors held Alzamend Neuro (ALZN) as of Q2 2026, down from 13 in Q1 2026.
- Funds reported $3.26M of Alzamend Neuro stock for Q2 2026, up 351% quarter-over-quarter.
- 2 funds opened new Alzamend Neuro positions in Q2 2026 and 3 closed out, a net change of -1 holder.
- The largest Alzamend Neuro buyer in Q2 2026 was KMT Wealth Management, an estimated $1.47M added.
- The largest Alzamend Neuro seller in Q2 2026 was Geode Capital Management, an estimated $21.4K sold.
Based on aggregated 13F filings for Q2 2026.